Gridline Peptides LLC provides a precision-formulated CJC-1295 + Ipamorelin blend, combining a growth hormone–releasing hormone (GHRH) analog with a selective ghrelin receptor agonist. This dual-peptide formulation is engineered for stability, consistency, and analytical precision in controlled laboratory environments.
This combination is designed to support structured in vitro investigation of synergistic peptide interactions across growth hormone signaling pathways, enabling analysis of receptor activation, signaling amplification, and downstream endocrine responses under controlled experimental conditions.
This product is intended strictly for in vitro laboratory evaluation and analytical research.
Product Specifications
Concentration:
• 5mg CJC-1295
• 5mg Ipamorelin
Format: Lyophilized white crystalline powder blend
Purity: >98% (each component)
Molecular Formula:
• CJC-1295: C₁₆₅H₂₆₉N₄₇O₄₆
• Ipamorelin: C₃₈H₄₉N₉O₅
Molecular Weight:
• CJC-1295: ~3647 g/mol
• Ipamorelin: 711.9 g/mol
CAS Number:
• CJC-1295: 863288-34-0
• Ipamorelin: 170851-70-4
Vial Size: 3ml sterile glass vial
Storage: Store refrigerated (2–8°C) under controlled laboratory conditions before and after reconstitution
Technical Overview & Research Applications
This peptide blend is utilized in structured research environments to investigate:
Growth Hormone Signaling Pathways: Analysis of GHRH receptor activation and ghrelin receptor interaction in controlled cellular models.
Peptide Synergy & Signal Amplification: Evaluation of combined peptide effects on signaling cascades and receptor-mediated responses.
Endocrine Pathway Modeling: Laboratory study of integrated hormone signaling systems and feedback mechanisms in vitro.
Receptor Binding Dynamics: Investigation of peptide affinity, receptor selectivity, and signaling duration.
Pulsatile Signaling Mechanisms: Examination of temporal patterns in peptide-driven signaling under controlled experimental conditions.
